BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
February 26 2024 - 8:00AM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”),
a global clinical-stage biopharmaceutical company focused on using
a groundbreaking technology platform for drug discovery and
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs, today announced that on
February 20, 2024, the Company received a written notification on
minimum bid price compliance (the “Notification Letter”) from The
Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained
compliance with the minimum bid price requirement set forth in
Nasdaq Listing Rule 5550(a)(2). In the Notification Letter, the
staff of Nasdaq has determined that for the 10 consecutive business
days from February 5, 2024 to February 16, 2024, the closing bid
price of the Company’s ordinary shares had been at $1.00 per share
or greater. Accordingly, the bid price deficiency matter as
previously disclosed is now closed.
In addition, on February 20, 2024, the Company
received a written notification on periodic filing compliance (the
“Letter”) from Nasdaq that it has met the periodic filing
requirement for Nasdaq Listing Rule 5250(c)(2) (the “Rule”). In the
Letter, the staff of Nasdaq has determined the Company complies
with the Rule as the Company filed its Form 6-K for the period
ended June 30, 2023 on February 2, 2024. Accordingly, the filing
delinquency matter as previously disclosed is now closed.
About BeyondSpringBeyondSpring
(NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company
focused on developing innovative therapies to improve clinical
outcomes for patients with high unmet medical needs. The Company is
advancing its first-in-class lead asset, Plinabulin, as a direct
anti-cancer agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. Its pipeline also includes three
preclinical immuno-oncology assets. Additionally, BeyondSpring’s
subsidiary, SEED Therapeutics, leverages a proprietary targeted
protein degradation (TPD) drug discovery platform and has an
initial R&D collaboration with Eli Lilly. Learn more by
visiting https://beyondspringpharma.com.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Sep 2024 to Oct 2024
BeyondSpring (NASDAQ:BYSI)
Historical Stock Chart
From Oct 2023 to Oct 2024